The utilization status of aspirin for the secondary prevention of ischemic stroke

被引:6
作者
Ke Xian-jun [1 ]
Yu Yong-fei [1 ]
Guo Zhen-li [1 ]
Xu Kang [1 ]
Hai Hong [1 ]
Zhang Ai-he [1 ]
Jiang Hong [1 ]
Peng Hong [1 ]
机构
[1] Peoples Hosp E&W Lake Dist, Dept Neurol, Wuhan 430040, Hubei, Peoples R China
关键词
ischemic stroke; aspirin; secondary prevention; ATTACK;
D O I
10.3760/cma.j.issn.0366-6999.2009.02.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The present study was aimed to investigate the usage of aspirin for the secondary prevention of ischemic stroke, evaluate the correlated factors, and analyze the reasons for not taking and irregularly taking aspirin. Methods The patients in this group were all stroke survivors who have formerly been diagnosed with a cerebral infarction or transient ischemic attack (TIA) in our hospital. We investigated their use of aspirin over a three-year period following their hospitalization. According to the patients' aspirin usage, they were divided into treatment and non-treatment groups. In addition, the reasons for not taking or irregularly taking aspirin were analyzed in the two groups. Results A total of 1240 patients were studied, including 367 (29.60%) in the treatment group and 873 (70.40%) cases in the non-treatment group. In addition, 201 (16.20%) cases in the treatment group had been regularly taking aspirin (50-325 mg of aspirin daily) for 1 to 3 years or longer. The results demonstrated that the main reasons for not taking aspirin in this study were related to patients' concerns regarding the side effects of taking aspirin (46.45%), as well as the doctors' inadequacy in informing their patients to take aspirin (38.71%). The major reasons for patients to irregularly take aspirin were that the doctors did not notify the length of aspirin usage to their patients (41.57%), and that doctors did not prescribe aspirin upon the patients' follow-up visit (26.51%). Conclusion The most effective way to increase patient's compliance for aspirin consumption is to promote the guidelines for stroke treatment and to relay these advances in stroke therapy to the patient.
引用
收藏
页码:165 / 168
页数:4
相关论文
共 13 条
[1]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[2]  
[Anonymous], 1988, STROKE, V19, P512
[3]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[4]  
*CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53
[5]   European stroke prevention study .2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke [J].
Diener, HC ;
Cunha, L ;
Forbes, C ;
Sivenius, J ;
Smets, P ;
Lowenthal, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1996, 143 (1-2) :1-13
[6]   THE UNITED-KINGDOM TRANSIENT ISCHEMIC ATTACK (UK-TIA) ASPIRIN TRIAL - FINAL RESULTS [J].
FARRELL, B ;
GODWIN, J ;
RICHARDS, S ;
WARLOW, C .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1991, 54 (12) :1044-1054
[7]   Secondary prevention of recurrent stroke [J].
Hankey, GJ .
STROKE, 2005, 36 (02) :218-221
[8]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762
[9]   Antithrombotic drugs in secondary stroke prevention among a community dwelling older population [J].
Landi, F ;
Cesari, M ;
Onder, G ;
Zamboni, V ;
Lattanzio, F ;
Russo, A ;
Barillaro, C ;
Bernabei, R .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (08) :1100-1104
[10]  
Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74